Welcome to our dedicated page for Werewolf Therapeutics SEC filings (Ticker: HOWL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Werewolf Therapeutics, Inc. (Nasdaq: HOWL) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biopharmaceutical company developing conditionally activated immune therapies, Werewolf uses its filings to report on financial condition, clinical progress, governance matters, and material corporate events.
Investors reviewing HOWL filings will find Form 8‑K current reports describing key developments such as pipeline and business updates, clinical data summaries for WTX-124 and WTX-330, strategic partnering objectives, and notices related to Nasdaq listing requirements. Results of operations and financial condition for specific quarters are furnished through 8‑K items that reference accompanying earnings press releases and corporate presentations.
Through its periodic reports and exhibits, Werewolf outlines the status of its PREDATOR platform, INDUKINE cytokine prodrugs, and INDUCER T cell engager programs, along with forward-looking statements that detail development timelines, regulatory engagement plans, and cash runway expectations. Governance-related disclosures, including board composition and audit committee matters, also appear in the company’s 8‑K filings.
On Stock Titan, HOWL filings are supplemented with AI-powered summaries that explain the significance of each document in clear language. Users can quickly understand the main points of lengthy filings, identify references to clinical trial updates, partnering strategies, or listing compliance, and navigate to specific sections of interest. Real-time updates from EDGAR help ensure that new filings are surfaced promptly, while access to historical documents allows for analysis of how Werewolf’s clinical pipeline, risk disclosures, and corporate priorities have evolved over time.
Werewolf Therapeutics (HOWL) reported insider stock sales by affiliated reporting persons. The group executed open‑market sales under a Rule 10b5‑1 plan dated September 24, 2025. Transactions included 140,488 shares on November 4 at a weighted average price of $1.22, 47,950 shares on November 5 at $1.22, and 54,452 shares on November 6 at $1.21.
Following these trades, the reporting persons collectively reported 5,904,720 shares beneficially owned on an indirect basis. The filing indicates the reporting persons are a director and 10% owner, and that the submission was made by more than one reporting person.
Werewolf Therapeutics (HOWL) filed its Q3 2025 report, highlighting continued operating losses and a liquidity warning. The company reported a Q3 net loss of
Cash and cash equivalents were
R&D expense was
Werewolf Therapeutics furnished a press release announcing financial results for the quarter ended September 30, 2025.
The company reported this under Item 2.02 of an 8-K on November 4, 2025, and stated the information, including Exhibit 99.1, is furnished and not deemed filed under the Exchange Act.
The filing also includes a caution regarding forward-looking statements.
Werewolf Therapeutics (HOWL) director Luke Evnin reported open‑market sales of common stock made under a Rule 10b5‑1 plan dated September 24, 2025. The sales occurred on 10/30/2025, 10/31/2025, and 11/03/2025.
He sold 55,795 shares at a weighted average price of $1.43 (range $1.365–$1.55), 73,192 shares at $1.28 (range $1.205–$1.415), and 60,369 shares at $1.29 (range $1.245–$1.33). Following these transactions, 3,943,359 shares were reported as beneficially owned indirectly through affiliated entities.
Werewolf Therapeutics (HOWL): A reporting group affiliated with MPM BioImpact/MPM BioVentures, identified as a Director and 10% Owner, reported open‑market sales executed under a Rule 10b5‑1 plan dated September 24, 2025. The group sold 86,936 shares on 10/30/2025 at a weighted average price of $1.43, 114,044 shares on 10/31/2025 at $1.28, and 94,063 shares on 11/03/2025 at $1.29.
Following these transactions, the group reported indirect beneficial ownership of 6,355,717 shares, then 6,241,673 shares, and 6,147,610 shares, respectively. Footnotes state the sales were made across multiple affiliated entities, with price ranges of $1.365–$1.55 on 10/30, $1.205–$1.415 on 10/31, and $1.245–$1.33 on 11/03, and that each reporting person disclaims beneficial ownership beyond pecuniary interest.
Werewolf Therapeutics (HOWL): A director and 10% owner reported open‑market sales executed under a Rule 10b5‑1 plan dated September 24, 2025. The transactions were: 86,936 shares at a weighted average price of $1.43 on October 30, 2025; 114,044 shares at a weighted average price of $1.28 on October 31, 2025; and 94,063 shares at a weighted average price of $1.29 on November 3, 2025.
Following these sales, the filer reported 6,147,610 shares beneficially owned indirectly. The filing lists multiple affiliated entities as holders and confirms the plan‑based nature of the trades.
Werewolf Therapeutics (HOWL) director Luke Evnin reported open‑market sales of common stock executed under a Rule 10b5‑1 plan dated September 24, 2025.
He sold 46,664 shares on 10/27/2025 at a weighted average price of $1.72, 44,327 shares on 10/28/2025 at $1.64, and 86,154 shares on 10/29/2025 at $1.55. Following these transactions, he beneficially owned 4,132,715 shares indirectly.
Footnotes state the sales were made across affiliated entities and that prices reflect weighted averages with full trade‑level details available upon request.
Werewolf Therapeutics (HOWL): insider sales reported by MPM-affiliated holders. Reporting persons associated with MPM BioImpact/MPM BioVentures, identified as a Director and 10% Owner, disclosed open‑market sales executed pursuant to a Rule 10b5‑1 plan dated September 24, 2025.
Sales occurred on three dates: 72,709 shares on 10/27/2025 at a weighted average price of $1.72 (individual trades ranged $1.675–$1.82); 69,068 shares on 10/28/2025 at a weighted average price of $1.64 (range $1.605–$1.70); and 134,240 shares on 10/29/2025 at a weighted average price of $1.55 (range $1.51–$1.62).
Following these transactions, the reporting group’s beneficial ownership (indirect) was 6,645,961 shares after 10/27, 6,576,893 shares after 10/28, and 6,442,653 shares after 10/29, held across affiliated funds as detailed in the footnotes.
Werewolf Therapeutics (HOWL): Insider Form 4 filing reports sales by entities affiliated with MPM/UBS Oncology, identified as a director and 10% owner. The transactions were made pursuant to a Rule 10b5-1 plan dated September 24, 2025.
On October 27, 2025, 72,709 shares were sold at a weighted average price of $1.72 (range $1.675–$1.82), leaving 6,645,961 shares beneficially owned. On October 28, 2025, 69,068 shares were sold at a weighted average price of $1.64 (range $1.605–$1.70), leaving 6,576,893 shares beneficially owned. On October 29, 2025, 134,240 shares were sold at a weighted average price of $1.55 (range $1.51–$1.62), leaving 6,442,653 shares beneficially owned.
The filing attributes sales and post-transaction holdings across several affiliated funds and managers and notes that each reporting person disclaims beneficial ownership beyond their pecuniary interest.
Werewolf Therapeutics, Inc. reported a material event notifying that it is presently non-compliant with Nasdaq listing rule 5605(c)(2) because of the passing of director Dr. Lazarus. The company cites Nasdaq Listing Rule 5605(c)(4)(B), which provides a cure period to restore compliance. That cure period will end on the earlier of the company’s next annual meeting of stockholders or